1421372-94-2

Basic information

• Product Name: N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine
• Synonyms: N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine;2-PyriMidinaMine, N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methyl-1H-indol-3-yl)-;N-(4-Fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)-2-pyrimidinamine;(4-Fluoro-2-methoxy-5-nitro-phenyl)-[4-(1-methyl-1h-indol-3-yl)-pyrimidin-2-yl]-amine;N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine;AZD9291 1;N-(4-fluoro-2-methoxy-5-nitrophenyl)- 4-(1-methylindol-3-yl)pyrimidin-2-amine(AZD9291 Intermediate 2);EOS-61221
• CAS NO: 1421372-94-2
• Molecular Formula: C₂₀H₁₆FN₅O₃
• Molecular Weight: 393.3711432
• EINECS: -0
• Product Categories: AZD9291
• Mol File: 1421372-94-2.mol
• Article Data: 33

Chemical Properties

• Boiling Point: 639.3±65.0 °C(Predicted)
• Appearance: /
• Density: 1.41±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• Solubility: DMSO (Slightly, Heated)
• PKA: 2.02±0.10(Predicted)
• CAS DataBase Reference: N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine(1421372-94-2)
• EPA Substance Registry System: N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine(1421372-94-2)

Safety Data

• Hazardous Substances Data: 1421372-94-2(Hazardous Substances Data)

Usage

Description

N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine is a complex organic compound characterized by its unique molecular structure. It is a derivative of pyrimidinamine, featuring a fluoro, methoxy, and nitro group on the phenyl ring, and a methylindole moiety attached to the pyrimidine core. N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine is known for its potential applications in the pharmaceutical and chemical industries due to its specific molecular interactions and properties.

Uses

Used in Pharmaceutical Industry:
N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine is used as a reagent for the synthesis of dihydropyrroloquinoline derivatives. These derivatives possess significant anticancer activity, particularly as modulators of the epidermal growth factor receptor (EGFR). The compound is specifically designed to inhibit the L858R/T790M mutation, which is a common resistance mutation in non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors.
The application reason for using N-(4-fluoro-2-Methoxy-5-nitrophenyl)-4-(1-Methylindol-3-yl)pyriMidin-2-aMine in this context is its ability to form dihydropyrroloquinoline derivatives with potent anticancer properties. These derivatives can effectively target and inhibit the EGFR L858R/T790M mutation, providing a potential therapeutic strategy for overcoming resistance to EGFR-targeted therapies in lung cancer treatment.

Upstream product

• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 1032452-86-0 2-chloro-4-(1'-methyl-1H-indol-3-yl)pyrimidine 
• 1075705-01-9 4-fluoro-2-methoxy-5-nitro-phenylamine 
• 104-15-4 toluene-4-sulfonic acid 
• 367-25-9 2,4-difluorophenylamine 
• 123344-02-5 5-amino-2,4-difluoronitrobenzene 
• 603-76-9 1-methylindole 
• 450-91-9 4-fluoro-2-methoxyaniline 
• 120-72-9 indole 
• 945016-63-7 3-(2-chloro-pyrimidin-4-yl)-1H-indole 

Downstream Products

• 1421373-88-7 C₂₉H₃₃N₇O₂ 
• 1421373-99-0 Ν-(4-methoxy-2-(methyl(2-(methylamino)ethyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide 
• 1421372-66-8 N?2?[[2?(dimethylamino)ethyl]methylamino]?4?methoxy?5?[[4?(1?methyl?1H?indole-3-yl)-2-pyrimidinyl]amino]aniline 
• 1421372-69-1 4-[(3R)-3-dimethylaminopyrrolidin-1-yl]-6-methoxy-N-[4-(1-methylindol-3-yl)pyrimidin-2-yl]benzene-1,3-diamine 
• 1421372-75-9 6-methoxy-N¹-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)-4-(4-methylpiperazin-1-yl)benzene-1,3-diamine 
• 1421372-81-7 4-(3-(dimethylamino)cycloazane-1-yl)-6-methoxy-N₁-[4-(1-methylindol-3-yl)pyrimidine- 2-yl]benzene-1,3-diamine 
• 1421373-12-7 4-[(3S)-3-dimethylaminopyrrolidin-1-yl]-6-methoxy-N'-{4-(1-methylindol-3-yl)pyrimidin-2-yl}benzene-1,3-diamine 
• 1421373-33-2 tert-butyl N-[2-[[5-methoxy-4-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]-2-(prop-2-enoylamino)phenyl](methyl)amino]ethyl]-N-methylcarbamate 
• 1421373-34-3 tert-butyl (2-((2-amino-5-methoxy-4-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)(methyl)amino)ethyl)(methyl)carbamate 
• 1421373-36-5 3-chloro-N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)propanamide 
• 1421373-65-0 [N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)propen-2-amide] 
• 1421373-66-1 N-(2-(N-(2-(dimethylamino)ethyl)-N-methylamino)-4-methoxy-5-((4-(1-methyl-1H-indole-3-yl)pyrimidine-2-yl)amino)phenyl)acrylamide methanesulfonate 
• 1421373-68-3 C₂₉H₃₃N₇O₂ 
• 1421373-71-8 EB₁₀₄ 

Relevant articles and documents

Discovery of highly potent and selective EGFRT790M/L858R TKIs against NSCLC based on molecular dynamic simulation

Epidermal growth factor receptor (EGFR) is the most attractive target for drug research in non-small cell lung cancer (NSCLC). There have been three generation drugs developed to treat of NSCLC. The third-generation EGFR tyrosine kinase inhibitors (TKIs)

Design, synthesis and structure-activity relationship studies of 4-indole-2-arylaminopyrimidine derivatives as anti-inflammatory agents for acute lung injury

Acute lung injury/acute respiratory distress syndrome (ALI/ARDS), a clinically high mortality disease, has not been effectively treated till now, and the development of anti-acute lung injury drugs is imminent. Acute lung injury was efficiently treated by inhibiting the cascade of inflammation, and reducing the inflammatory response in the lung. A series of novel compounds with highly efficient inhibiting the expression of inflammatory factors were designed by using 4-indolyl-2-aminopyrimidine as the core skeleton. Totally eleven 4-indolyl-2-arylaminopyrimidine derivatives were designed and synthesized. As well, the related anti-ALI activity of these compounds was evaluated. Compounds 6c and 6h showed a superior activity among these compounds, and the inhibition rate of IL-6 and IL-8 release ranged from 62% to 77%, and from 65% to 72%, respectively. Furthermore, most of compounds had no significant cytotoxicity in vitro. The infiltration of inflammatory cells into lung tissue significantly reduced by using compound 6h (20 mg/kg) in the ALI mice model, which achieved the effect of protecting lung tissue and improving ALI. In addition, the inflammatory response was inhibited by using compound 6h through inhibiting phosphorylation of p-38 and ERK in MAPK signaling pathway, and resulted in protective effect on ALI. These data indicated that compound 6h showed good anti-inflammatory activity in vitro and in vivo, which was expected to become a leading compound for the treatment of ALI.

Compound for inhibiting three-mutant epidermal growth factor receptor tyrosine kinase and application thereof

The invention discloses a compound for inhibiting three-mutant epidermal growth factor receptor tyrosine kinase, and is characterized in that the structural formula is as follows. Among them: Substituent R1 . One of: Substituent R2 . One of: The substituent X is H or Cl. Substituent R3 To H. One of the following.